逢甲大學logo

:::

APPLY NOW 

 

 INTERNATIONAL STUDENTS SERVICES

Ms.Huang  
+886-4-24517250 ext.2496
Mon. to Fri.  09:00-12:00, 13:30-17:00
mhuang@fcu.edu.tw

IEET 

:::
You are here: : Home > FEATURED NEWS
  • Go Back

FEATURED NEWS

FCU researcher develops advanced medical dressing for diabetic patients

  • HITS: 927
  •  
Share To:

According to research statistics, 250 million people suffer from diabetes worldwide. In Taiwan, there are about two million diabetes patients. If not well controlled, diabetes can lead to many complications. For example, if a cut or wound becomes infected, it may not heal well or quickly.
  On January 8, Professor Tse-Hao Ko of the FCU Department of Materials Science and Engineering announced the development of the world’s most advanced wound and burn dressing. This invention is the result of a National Science Council-supported research project. Three technologies are incorporated including PAN-based activated carbon fiber, silver-coated activated carbon fiber cloth and antimicrobial composition and wound dressing. This dressing has many applications, such as for the protection and enhanced healing of wounds, burns, and pressure sores. 
 Following testing in Taiwan and the U.S., this dressing has been found to be nearly 100% effective in protecting against certain types of bacteria. It can be used on general sores and wounds, ulcers, surgical incisions and all levels of burns, as well as on wounds of diabetic patients that are not healing well. This dressing helps to relieve inflammation and pain at the wound site and promotes healing. This dressing is targeted toward chronic disease sufferers, such as those with diabetes, and may provide a glimmer of hope for diabetic patients facing amputation due to slowly healing sores or wounds.
  These wound care dressings are produced by Bio-medical Carbon Technology Co., Ltd. This is the first Asian manufacturer to develop advanced silver coated activated carbon fiber cloth for wound dressings. This is the only wound dressing produced for diabetic patients and it is expected to be marketed in North America, Europe, the Middle East and Asia.